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Abstract
Inhaled prostanoids and phosphodiesterase (PDE) inhibitors have been suggested for treatment of
severe pulmonary hypertension. In catheterized rabbits with acute pulmonary hypertension
induced by continuous infusion of the stable thromboxane analogue U46619, we asked whether
sildenafil (PDE1/5/6 inhibitor), motapizone (PDE3 inhibitor) or 8-Methoxymethyl-IBMX (PDE1
inhibitor) synergize with inhaled iloprost. Inhalation of iloprost caused a transient pulmonary artery
pressure decline, levelling off within <20 min, without significant changes in blood gases or systemic
hemodynamics. Infusion of 8-Methoxymethyl-IBMX, motapizone and sildenafil caused each a dose-
dependent decrease in pulmonary artery pressure, with sildenafil possessing the highest efficacy and
at the same time selectivity for the pulmonary circulation. When combining a per se ineffective dose
of each PDE inhibitor (200 µg/kg × min 8-Methoxymethyl-IBMX, 1 µg/kg × min sildenafil, 5 µg/kg
× min motapizone) with subsequent iloprost nebulization, marked amplification of the prostanoid
induced pulmonary vasodilatory response was noted and the area under the curve of PPA reduction
was nearly threefold increased with all approaches, as compared to sole iloprost administration.
Further amplification was achieved with the combination of inhaled iloprost with sildenafil plus
motapizone, but not with sildenafil plus 8MM-IBMX. Systemic hemodynamics and gas exchange
were not altered for all combinations. We conclude that co-administration of minute systemic
doses of selective PDE inhibitors with inhaled iloprost markedly enhances and prolongs the
pulmonary vasodilatory response to inhaled iloprost, with maintenance of pulmonary selectivity
and ventilation perfusion matching. The prominent effect of sildenafil may be operative via both
PDE1 and PDE5, and is further enhanced by co-application of a PDE3 inhibitor.
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Introduction
Severe pulmonary hypertension is a fatal disease with
short life expectancy [1,2]. Continuous intravenous
administration of prostacyclin was documented to
improve exercise capacity and survival in patients with idi-
opathic pulmonary arterial hypertension (IPAH, formerly
primary pulmonary hypertension, PPH) [1,3]. Possible
disadvantages of this approach are catheter related septic
events and systemic side effects including serious systemic
hypotension. In patients with pulmonary hypertension
associated with pulmonary fibrosis, systemic administra-
tion of vasodilators results in ventilation perfusion mis-
match and impairment of arterial oxygenation. Inhalation
of aerosolized iloprost, a long-acting prostacyclin ana-
logue, has been shown to cause selective pulmonary
vasodilatation in both primary and secondary pulmonary
hypertension [4-6]. Long term use of nebulized iloprost
was described to improve exercise capacity, event-free sur-
vival and hemodynamics in severe IPAH, and this finding
was supported by a randomized, controlled phase III
study in patients in NYHA class III and IV [7].
The use of aerosolized iloprost for acute pulmonary
vasodilatation and putative long-term anti-remodeling
effects in severe chronic pulmonary hypertension does,
however, demand 6 – 12 inhalations per day, as the
vasodilatory effect levels off within ~60 min post nebuli-
zation. Against this background, recent studies addressed
the impact of selective phosphodiesterase (PDE) inhibi-
tors on prostacyclin-induced acute pulmonary vasodilata-
tion, reporting a marked amplification and prolongation
of the vasodilatory response to inhaled PGI2 [8]. PDEs are
enzymes that inactivate cyclic AMP and cyclic GMP, the
second messengers of prostacyclin and NO [9,10]. The
characterization of the various PDEs currently known has
largely profited from the employment of selective PDE
inhibitors. Concerning the lung vasculature, the presence
of the PDE isoenzymes 1, 3, 4 and 5 in the cytosolic and
particulate phases (homogenized human pulmonary
artery tissue) has been demonstrated [11].
Phosphodiesterase 1 is Ca2+/calmodulin dependant and
hydrolyzes both cGMP and cAMP. PDE3 does possess
high affinity for both cAMP and cGMP, with Vmax for
cAMP usually greater than that for cGMP [9,12]. PDE4
enzymes are characterized by their high affinity to cAMP,
with cGMP representing a very poor substrate. In contrast,
PDE 5 is cGMP-specific and was found to be highly
expressed in lung tissue [13,14].
Recent clinical data suggest that the PDE 1/5/6 inhibitor
sildenafil (IC50 values 280 nM, 3.5 nM and 37 nM, respec-
tively [15]), which has been approved for the treatment of
erectile dysfunction, is an effective pulmonary vasodilator
in patients with pulmonary arterial hypertension [16-21].
Based on a very recent positive phase III study, sildenafil
has been approved for the treatment of pulmonary hyper-
tension in US. Interestingly, it has been shown that silde-
nafil synergizes with inhaled iloprost in patients with
pulmonary hypertension [16,22]. Hitherto no attempt
was undertaken to clarify, which of the PDEs addressed by
sildenafil is the most relevant for the effect of this agent in
the pulmonary circulation, and whether combinations
with further selective PDE inhibitors might even enhance
the sildenafil effect. To address this issue, systemic appli-
cation of per se ineffective doses of specific PDE inhibitors
in companion with inhalation of iloprost was undertaken
in an experimental model of pulmonary hypertension in
the present study.
Methods
Materials
8-Methoxymethyl-IBMX (8-Methoxymethyl-3-isobutyl-1-
methylxanthine) and the thromboxane-A2  mimetic
U46619 were supplied by Sigma (Deishofen, Germany).
Sildenafil was obtained from Pfizer (Sandwich, UK) and
iloprost (Ilomedin®) was obtained from Schering A.G.
(Berlin, Germany). All other chemicals and drug supplies
were from standard commercial sources.
Surgical Preparation
New zealand white rabbits weighing between 2.8 and 3.1
kg of either sex were anesthetized with a mixture of xyla-
zine and ketamine and anticoagulated with 200 U/kg
heparin [8]. Anaesthesia was maintained by a constant
intravenous infusion of xylazine and ketamine through
the right peripheral ear vein. Animals were tracheos-
tomized and ventilated using a volume-controlled respi-
rator (cat ventilator, Hugo Sachs Elektronik, March
Hugstetten, Germany) with 8 ml/kg bodyweight and a fre-
quency of 40 min-1. FiO2 was set at 0.5 and a positive
endexpiratory pressure of 0.5 mmHg was used through-
out. The left A. carotis was cannulated for arterial pressure
monitoring and a pulmonary artery catheter (4 Fr, Braun,
Melsungen, Germany) was inserted into the pulmonary
artery through the right external jugular vein.
Hemodynamics and blood gases
Mean pulmonary artery pressure (PPA) and mean aortic
pressure (PSA) were continuously recorded with fluid-
filled force transducers (Braun, Combitrans, FRG). The
level of the left atrium was set to zero. As described previ-
ously, pulmonary artery occlusion pressure was measured
by gentle forwarding of the catheter to wedge position
[23]. Pulmonary and systemic vascular resistances were
calculated by standard formulas. As described previously,
cardiac output (CO) was calculated by using the Fick prin-
ciple [8]. Briefly, arterial and venous blood samples (1
ml) were stored on ice, and hemoglobin and oxygen satu-
ration were measured using an OSM2 HemoximeterRespiratory Research 2005, 6:76 http://respiratory-research.com/content/6/1/76
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(Radiometer-Copenhagen, Denmark). Oxygen uptake of
the animals was measured online (Labotect O2-Control-
ler, Goettingen, Germany).
Nebulization
Iloprost was nebulized by means of an ultrasonic neb-
ulizer (Pulmo Sonic 5500, DeVilbiss Medizinische
Produkte GmbH, Langen, Germany) which produces an
aerosol with a mass median aerodynamic diameter
(MMAD) of 4.5 µm and a geometric standard deviation
(GSD) of 2.3. The nebulizer was placed in the inspiratory
limb of the ventilation system as described previously
[24].
Experimental protocols
U46619 was continuously infused (dose range 0.5 to 2
µg/kg min) to increase pulmonary artery pressure from
~16 at baseline to ~26 mmHg within 20 min. As described
previously, stable pulmonary hypertension is established
by this approach [8]. Dose-effect curves of intravenous
sildenafil, motapizone and 8MM-IBMX were established
after reaching a stable pressure plateau, performing short-
term infusions (10 min) with randomized doses of these
agents. Hemodynamics and blood gases were measured at
the end of the 10 min infusion period. A total dose of 0.4
± 0.08 µg/kg iloprost, nebulized within a 10 min aerosoli-
zation maneuver, was used throughout all studies with
iloprost inhalation. In the group with sole administration
of this inhalative agent, the nebulization was performed
after reaching a stable pressure plateau. In the combina-
tion experiments, the PDE inhibitors were administered
intravenously at a dose which by itself did not reduce PAP
significantly as short-term infusion (10 min), and iloprost
was nebulized subsequently.
Data analysis
All data are given as means ± SEM. Differences between
the different groups were assessed by use of analysis of
variance and Student-Newman-Keuls test for multiple
comparisons with a p value < 0.05 regarded to be
significant.
Results
Baseline and U46619-induced pulmonary hypertension
The continuous infusion of 1.3 ± 0.9 µg/kg min U46619
resulted in a significant increase of pulmonary artery pres-
sure (PPA) to 26 mmHg as compared to 16 mmHg prior to
U46619 (Table 1). Cardiac output and mean systemic
pressure (PSA) did not change significantly. The pulmo-
nary vascular resistance increased from 275 to 592 dyne/s
cm-5 m2. No significant changes in blood gases were meas-
ured as compared to baseline values.
Dose-effect curves of PDE-inhibitors
Intravenous sildenafil, motapizone and 8MM-IBMX
reduced PPA in a dose-dependent manner (Fig. 1A), with
the dose-effect curves differing by ~two orders of magni-
tude between sildenafil and the two other compounds. As
depicted in Fig. 1B, this pulmonary vasodilatation was
accompanied by a significant systemic arterial pressure
decrease in case of motapizone (dose range 6 – 600 µg/kg
× min) and 8MM-IBMX (dose range 70 – 1500 µg/kg ×
min), but not in case of sildenafil (dose range 0.1 – 10 µg/
kg × min).
Nebulization of iloprost
Inhalation of 0.4 µg/kg aerosolized iloprost resulted in a
significant decrease in U46619-induced pulmonary
hypertension, from 25.8 ± 0.6 to 22.7 ± 0.4 mmHg PPA
immediately after stop of nebulization (Table 1, Fig.
2a,b). Pulmonary vascular resistance decreased in
response to the prostanoid by 18% (Fig. 3). No significant
changes in blood gases, cardiac output and systemic arte-
rial pressure were noted (Fig. 4). Within ~18 min, 95% of
the U46619-induced PPA plateau was reached again. The
calculated area under the curve (AUC) was 470 ± 49
%∆ PPA × min (Fig. 5).
Combined administration of a per se ineffective 
intravenous PDE-inhibitors and iloprost nebulization
In the presence of sub-threshold motapizone (5 µg/kg ×
min), the iloprost-induced vasodilatation was signifi-
cantly increased, with a maximum PPA drop of 40.6 ±
4.6% of the U46619-induced pressor response, as com-
pared to 23.8 ± 2.2% for sole iloprost nebulization (Fig.
2a). In addition, motapizone enhanced the iloprost
induced PVR reduction (37% versus 18%) (Fig. 3). More-
over, the duration of the vasodilatory response, defined
by PPA values below 95% of the U46619-induced pressure
plateau, was significantly prolonged, from 18 min to 50
min. The AUC was markedly increased to 1351 ± 192
%∆ PPA × min (p < 0.01; Fig. 5). Comparable efficacy was
noted for intravenous sub-threshold sildenafil (1 µg/kg ×
min), which enhanced the maximum PPA drop to 36.3 ±
3.6% of the U46619-induced pressor response and PVR
reduction to 27%, prolonged the post-nebulization
vasodilatory effect to 50 min, and increased the AUC to
1183 ± 136 %∆ PPA × min. The combination of sub-thresh-
old 8MM-IBMX with iloprost again enhanced the
maximum PPA and PVR decrease in response to iloprost
aerosolization and prolonged the vasodilatation to 50
min, with AUC values ranging at 1206 ± 177 %∆ PPA ×
min. No further amplification of the iloprost induced
vasodilation was achieved by combination with sub-
threshold doses of sildenafil plus 8MM-IBMX with an
AUC of 1268 ± 115 %∆ PPA × min and an amplification of
the iloprost effect on PPA decrease of 56.4 ± 4.0% (Fig. 2b).
In contrast, further amplification was noted for theRespiratory Research 2005, 6:76 http://respiratory-research.com/content/6/1/76
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combination of inhaled iloprost with sub-threshold doses
of sildenafil plus motapizone, which enhanced the PPA
drop to 54.6 ± 3.7%, the PVR drop to 35% and increased
the AUC to 1993 ± 166 %∆ PPA × min. In none of the
groups, any significant decrease in systemic arterial pres-
sure (Fig. 4) or deterioration of gas exchange (Table 1) was
noted.
Discussion
The inhalation of nebulized prostanoids for treatment of
pulmonary hypertension is an approach targeting selec-
tive vasodilatation in well ventilated and aerosol accessi-
ble lung regions. This strategy has been developed to
circumvent side effects of the conventional intravenous
therapy with prostacyclin, e.g. systemic hypotension and
ventilation-perfusion mismatch. As anticipated from pre-
vious studies in patients with severe pulmonary hyperten-
sion [4,5], aerosolization of iloprost was, indeed, effective
in causing lung vasorelaxation without any decrease in
systemic arterial pressure and any deterioration of gas
exchange in the present rabbit model. After completion of
the aerosolization maneuver, the iloprost effect levelled
off within 20 – 30 min, which is somewhat more rapid
than in the human system (45–90 min). This difference is
most likely due to some species variance in the kinetics of
the iloprost catabolic pathway: being chemically stable –
in contrast to prostacyclin – iloprost is converted to dinor-
and tetranor-iloprost metabolites via beta-oxidation [25].
The liver is known to be a major site of this catabolic path-
way, however, recent studies in isolated perfused rabbit
lungs demonstrated that the conversion of iloprost to
these beta-oxidation products also takes place in the lung
tissue itself [26].
Phosphodiesterases represent the major route for cAMP
and cGMP degradation in cells, thereby limiting the
downstream effects of adenylate and guanylate cyclase
activating agents such as prostacyclin or NO. Until now,
11 types of PDEs have been characterized, which differ in
substrate specificity and regulatory properties [9,27,28].
Within the lung, PDE 3 and 4 represent the major cAMP
hydrolyzing pathways [10], and monoselective inhibitors
of PDE 3 and PDE 4 have been shown to possess pulmo-
nary vasodilatory potency [8,11,29].
Motapizone is a highly selective PDE3 inhibitor, with an
IC50 value of 30 nM [30]. Thus, the finding that motapiz-
one infusion causes dose-dependent pulmonary
Table 1: Summarized data of hemodynamics and blood gases in rabbits with U46619-induced pulmonary hypertension and inhalation 
of iloprost in the absence and presence of sub-threshold intravenous PDE inhibitors.∆
Control/
U46619
U46619/Ilo U46619/Ilo/Sil U46619/Ilo/
8MM-IBMX
U46619/Ilo/
Mota
U46619/Ilo/
8MM-IBMX/Sil
U46619/Ilo/
Mota/Sil
Pre post pre post pre post pre post pre post pre post pre post
PSA, mmHg 111 ± 
4
105 ± 
3
111 ± 
3
111 ± 
3
106 ± 
3
105 ± 
2
107 ± 
2
104 ± 
4
100 ± 
3
96 
± 3
99 
± 3
97 
± 2
93 
± 4
92 
± 4
PPA, mmHg 15.9 ± 
0.3
25.9* ± 
0.4
25.8 ± 
0.6
22.7* ± 
0.4
25.7 ± 
0.2
21.8* ± 
0.3
24.8 ± 
0.7
21.1* ± 
0.8
27.3 ± 
1,1
21.0* ± 
0.6
25.0 ± 
0.4
20.4* ± 
0.3
24.7 ± 
0.4
19.3* ± 
0.4
CO, ml/min 555 ± 
23
544 ± 
38
432 ± 
27
452 ± 
25
444 ± 
19
488 ± 
35
393 ± 
24
437 ± 
29
417 ± 
21
446 ± 
15
454 ± 
27
505 ± 
30
501 ± 
35
555 ± 
52
PAOP, 
mmHg
7.2 ± 
1.2
7.6 ± 
0.8
8.0 ± 
1.1
7.3 ± 
1.3
7.7 ± 
0.9
7.4 ± 
1.1
7.7 ± 
0.8
7.6 ± 
1.2
6.9 ± 
1.3
7.3 ± 
1.1
7.7 ± 
1.2
7.7 ± 
1.1
7.8 ± 
0.8
7.2 ± 
1.1
PVRI, dyne/s 
cm-5 m2
275 ± 
34
592* ± 
49
725 ± 
39
599* ± 
37
713 ± 
58
519* ± 
44
765 ± 
67
543* ± 
63
861 ± 
64
540* ± 
71
670 ± 
75
442* ± 
52
593 ± 
56
383* ± 
61
PaO2, mmHg 226 ± 
17
199 ± 
12
183 ± 
12
177 ± 
10
191 ± 
6
203 ± 
4
228 ± 
7
188 ± 
12
201 ± 
7
197 ± 
11
171 ± 
10
173 ± 
11
179 ± 
10
174 ± 
14
PHa 7.42 ± 
0.02
7.35 ± 
0.02
7.37 ± 
0.03
7.32 ± 
0.01
7.36 ± 
0.02
7.32 ± 
0.02
7.41 ± 
0.02
7.38 ± 
0.02
7.33 ± 
0.01
7.31 ± 
0.01
7.35 ± 
0.02
7.34 ± 
0.02
7.33 ± 
0.02
7.29 ± 
0.01
PaCO2 mmHg 42.7 ± 
1.3
43.0 ± 
3.5
41.5 ± 
2.0
40.7 ± 
1.0
42.0 ± 
4.1
45.2 ± 
4.0
36.2 ± 
1.6
37.7 ± 
1.5
44.3 ± 
1.2
46.2 ± 
1.2
45.9 ± 
1.7
47.6 ± 
1.4
36.9 ± 
2.0
38.0 ± 
1.8
PvO2, mmHg 46.7 ± 
1.3
44.1 ± 
2.4
39.9 ± 
1.7
42.6 ± 
1.2
39.7 ± 
2.3
44.9 ± 
1.4
35.8 ± 
1.5
39.7 ± 
2.1
40.7 ± 
1.64
42.7 ± 
1.2
39.7 ± 
2.5
44.9 ± 
2.6
41.8 ± 
1.2
44.0 ± 
1.6
PHv 7.30 ± 
0.01
7.24 ± 
0.02
7.34 ± 
0.03
7.29 ± 
0.01
7.23 ± 
0.02
7.20 ± 
0.02
7.37 ± 
0.02
7.31 ± 
0.03
7.28 ± 
0.01
7.26 ± 
0.01
7.29 ± 
0.02
7.28 ± 
0.02
7.28 ± 
0.02
7.24 ± 
0.01
PvCO2, 
mmHg
49.8 ± 
0.9
54.9 ± 
1.2
48.9 ± 
2.3
49.7 ± 
1.1
59.2 ± 
1.6
60.6 ± 
1.4
44.6 ± 
2.5
44.9 ± 
2.5
52.4 ± 
1.4
54.2 ± 
1.4
53.8 ± 
2.0
52.9 ± 
2.2
42.5 ± 
2.3
45.9 ± 
1.6
∆  PSA, mean aortic pressure; PPA, mean pulmonary artery pressure; CO, cardiac output; PAOP, pulmonary artery occlusion pressure; PVR, 
pulmonary vascular resistance; PaO2, arterial PO2; pHa, arterial pH; PaCO2, arterial PCO2; PvO2, central venous PO2; pHv, central venous pH; 
PvCO2, central venous PCO2; Ilo, iloprost; Sil, sildenafil; 8MM-IBMX, 8-Methoxymethyl-3-isobutyl-1-methylxanthine; Mota, motapizone. The first 
two columns give summarized data for all groups. All other columns give pre- and post-iloprost nebulization data in animals undergoing preceding 
sub-threshold PDE-inhibitor infusion (n = 8 for each group). Asterisks indicate significant differences between pre and post-aerosolization values (* 
= p < 0.05).Respiratory Research 2005, 6:76 http://respiratory-research.com/content/6/1/76
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vasodilatation in intact rabbits with elevated pulmonary
artery pressure is well in line with previous observations
in this field. Notably, the motapizone effect was not pul-
monary selective: in the dose range from 10 to 1000 µg/kg
× min, both the pulmonary artery and the systemic artery
pressure declined in a parallel fashion.
PDE1 gene products are expressed in cardiac tissues from
several species [31,32]. A role of increased PDE1C
expression in the cardio-protective effect of the stable
prostacyclin derivative, 7-oxo-prostacyclin, indicates that
PDE1C variants may be involved in tissue responses to
cardiovascular stress [33]. In vascular smooth muscle cells
derived from different species, several reports demon-
strated PDE1 expression. PDE1C was shown to be present
in proliferating smooth muscle cells [31,34] and an
increased expression of PDE1A1 in rat aorta was shown to
Dose effect curves of different PDE inhibitors on U46619- elicited pulmonary hypertension (a) and systemic arterial  pressure (b) Figure 1
Dose effect curves of different PDE inhibitors on U46619-
elicited pulmonary hypertension (a) and systemic arterial 
pressure (b). (a) Pulmonary artery pressure drop (∆ PPA, in 
mmHg) and systemic arterial pressure drop (∆ PSA, in mmHg) 
(b) are given (mean ± SEM of 6 independent experiments 
each). PDE-inhibitors were applied in different doses as 
short-term infusion.
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Influence of iloprost nebulization and its combination with  sub-threshold doses of single (a) or combined (b) intrave- nous PDE inhibitors on U46619-elicted pulmonary  hypertension Figure 2
Influence of iloprost nebulization and its combination with 
sub-threshold doses of single (a) or combined (b) intrave-
nous PDE inhibitors on U46619-elicted pulmonary hyperten-
sion. Pulmonary artery pressure (PPA, in % of U46619-
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experiments each, SEM bars are missing when falling into 
symbol). Iloprost nebulization (Ilo aer; 0.4 µg/kg) is indicated 
by the horizontal bar. The PDE inhibitors were pre-applied 
as short-term infusion as follows: 200 µg/kg × min 8-Meth-
oxymethyl-IBMX, 1 µg/kg × min sildenafil, 5 µg/kg × min 
motapizone.
50
60
70
80
90
100
110
%
P
-4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68
Time [min]
Ilo aer
Ilo aer/Sildenafil
Ilo aer/8MM-IBMX
Ilo aer/Motapizone
Iloprost-Aerosol
P
A
'
50
60
70
80
90
100
110
%
P
-4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68
Time [min]
Ilo aer
Ilo aer/8MM-IBMX/Sildenafil
Ilo aer/Motapizone/Sildenafil
Iloprost-Aerosol
P
A
'
re 2BRespiratory Research 2005, 6:76 http://respiratory-research.com/content/6/1/76
Page 6 of 11
(page number not for citation purposes)
contribute to the development of nitroglycerin tolerance
[35].
Concerning the lung vasculature, only very limited data
on PDE1 expression is available [11]. Our group recently
observed that PDE1C is strongly upregulated in the pul-
monary artery media of human lungs with severe pulmo-
nary hypertension (R. Schermuly et al., non-published
results). It is in line with this notion that the selective
PDE1 inhibitor 8MM-IBMX induced dose-dependent pul-
monary vasodilation in the presently investigated acute
pulmonary hypertension model, however, without being
specific for the pulmonary circulation, as evident from the
parallel decline of systemic arterial pressure.
The cGMP-specific phosphodiesterase PDE 5 is abun-
dantly distributed in the lung tissue [13,14,36]. In a
hypoxia-induced model of pulmonary hypertension in
the rat, Cohen et al. demonstrated that the PDE 5
inhibitor E4021 selectively vasodilates the pulmonary cir-
culation when being applied intravenously [36], and this
observation was confirmed in a model of newborn lambs
with persistent pulmonary hypertension [37]. Another
specific PDE 5 inhibitor, E4010, has been shown to be a
selective pulmonary vasodilatator in a hypoxic rat model
of pulmonary hypertension [38]. Accordingly, the PDE 1/
5/6 inhibitor sildenafil, which is approved for treatment
of erectile dysfunction, was also recently shown to cause
preferential pulmonary vasodilatation even when being
systemically administered [39]. These data are well in line
Influence of iloprost nebulization and its combination with sub-threshold doses of intravenous PDE inhibitors on U46619- elicted pulmonary hypertension Figure 3
Influence of iloprost nebulization and its combination with sub-threshold doses of intravenous PDE inhibitors on U46619-
elicted pulmonary hypertension. Decrease in pulmonary vascular resistance (PVR, in %) at the end of the nebulization period is 
given (mean ± SEM of 8 independent experiments each). The PDE inhibitors were pre-applied as short-term infusion as fol-
lows: 200 µg/kg × min 8-Methoxymethyl-IBMX, 1 µg/kg × min sildenafil, 5 µg/kg × min motapizone. *, p < 0.05 as compared to 
pre-nebulization value.
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with the current finding in pulmonary hypertensive rab-
bits that intravenously infused sildenafil causes a doses-
dependent decrease in pulmonary artery pressure, virtu-
ally without any decline in systemic arterial pressure.
The rationale to combine cAMP-elevating agents, like
prostacyclin or the stable prostacyclin analogue iloprost,
with PDE3 inhibitors is obvious, and studies from our
group already showed a marked amplification and pro-
longation of the pulmonary vasodilatory response to aer-
osolized prostacyclin in the presence of type 3 PDE
inhibitors [8,29]. The present investigation demonstrates
that such synergistic effect also hold true for the PDE3
inhibitor motapizone and the longer acting agent ilo-
prost: in the presence of minute doses of intravenously
applied motapizone, the area under the curve of PPA
decrease in response to the standard inhaled iloprost dose
was nearly threefold increased, again without any decline
in systemic arterial pressure or any deterioration of gas
exchange being detectable.
Interestingly, similar potency to increase the response to
inhaled iloprost was also noted for subthreshold doses of
the PDE 1 inhibitor 8MM-IBMX. This might be antici-
pated to some extent, as PDE1 causes degradation of both
cAMP and cGMP (Fig. 6), thereby directly effecting
downstream signalling of iloprost, and indirectly modify-
ing this pathway via cGMP sensitive PDE inhibitors. The
Influence of iloprost nebulization and its combination with sub-threshold doses of single or combined intravenous PDE inhibi- tors on systemic arterial pressure (PSA) Figure 4
Influence of iloprost nebulization and its combination with sub-threshold doses of single or combined intravenous PDE inhibi-
tors on systemic arterial pressure (PSA). The experiments correspond to those in Fig. 2; the decrease in PSA (in % of baseline) at 
the end of the iloprost nebulization (Ilo aer) period is given (mean ± SEM of 8 independent experiments each).
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fact, however, that the area under the curve of PPA reduc-
tion was similarly augmented as in the presence of
motapizone (~threefold) suggests that PDE1 inhibitors
are worth to be taken into consideration for further strat-
egies to enhance beneficial prostanoid effects in the pul-
monary circulation.
Furthermore, the current study demonstrates that the PDE
1/5/6 inhibitor sildenafil also amplifies the pulmonary
vasodilatory response to inhaled iloprost, and that in this
respect subthreshold systemic doses of sildenafil are again
virtually as effective as subthreshold doses of the PDE3
inhibitor motapizone. This amplification of the iloprost-
induced PPA decrease again occurred without any decline
in systemic arterial pressure and any gas exchange distur-
bances. The mechanisms underlying this sildenafil effect
deserve further elucidation. Given the pharmacological
profile of this agent [40,41], it is unlikely that sildenafil
caused relevant direct inhibition of lung PDE 3 and 4,
thereby promoting prolongation of the half life of cAMP.
Its effect may, however, well be explained by the known
cross talk between the cAMP and the cGMP pathways:
PDE 3 is inhibited by intracellular cGMP with an IC50 of
0.1–1 µM [42]. A significant inhibition of PDE 5 by silde-
nafil may thus result in cGMP accumulation, given the
fact that there is some permanent baseline stimulation of
this pathway via endogenous NO, and next to causing per
se some vasodilatory effect, the sildenafil-induced cGMP
may particularly be effective via PDE 3 inhibition and
thereby enhanced sensitivity to inhaled iloprost. In
Influence of PDE inhibition on the area under the curve (AUC) of iloprost-induced decrease in pulmonary artery pressure (PPA) Figure 5
Influence of PDE inhibition on the area under the curve (AUC) of iloprost-induced decrease in pulmonary artery pressure 
(PPA). Measurements were performed from onset of iloprost nebulization (Ilo aer) until 68 min post aerosolization. AUC was 
calculated by standard techniques and is given as %∆ PPA × min. The maneuvers and dosages correspond to those depicted in 
Fig. 2. *, p < 0.05 as compared to sole iloprost nebulization; †, p < 0.05 as compared to all other groups.
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addition to such mode of action, supported by previous
studies in the cooperativity between the cGMP and the
cAMP axis in the lung vasculature [8,43], further (non-
cGMP related) effects of sildenafil in the pulmonary circu-
lation may involve inhibition of PDE1 (Fig. 5). This view
is supported by the above discussed efficacy of selective
PDE1 inhibition by 8-MM-IBMX. The IC50 of sildenafil
against PDE1 is about 280 nM [15], and although plasma
levels of sildenafil are not addressed in this study, these
levels could be achieved after sildenafil application.
Thus, both indirect inhibition of PDE3 by increased
cGMP and direct inhibition of PDE1 may explain the
effects of sildenafil on the iloprost-induced vasodilation.
Our studies in co-application of sildenafil with motapiz-
one on the one hand and 8-MM-IBMX on the other hand
do, however, favour the sildenafil-PDE1 axis: whereas the
combination of sildenafil with the PDE1 inhibitor 8MM-
IBMX did not further amplify the iloprost-induced vasodi-
lation over the effect of each agent alone, the combination
of sildenafil plus motapizone effected a further strong
amplification of the prostanoid induced vasodilation.
Besides being of interest as to the mode of action of
sildenafil, this finding suggests that an optimum strategy
to combine PDE inhibitors may result in even further aug-
mentation of pulmonary vascular prostanoid efficacy as
compared to the choice of one selective PDE inhibitor as
partner for the prostanoid. In conclusion, intravenous
administration of the PDE1 inhibitor 8MM-IBMX, the
PDE 3 inhibitor motapizone and the PDE 1/5/6 inhibitor
sildenafil causes dose-dependent pulmonary vasodilation
in a rabbit model of pulmonary hypertension, with silde-
nafil possessing selectivity for the lung vasculature. Most
interestingly, when applied in subthreshold doses, all
PDE inhibitors enhanced and markedly prolonged the
vasodilatory response to inhaled iloprost, without any
systemic pressure decline or deterioration of gas exchange
being detectable. Maximum efficacy was noted upon com-
Schematic depiction of the crosstalk between different phosphodiesterases (PDE) and the effects of PDE inhibitors on cGMP  and cAMP signaling Figure 6
Schematic depiction of the crosstalk between different phosphodiesterases (PDE) and the effects of PDE inhibitors on cGMP 
and cAMP signaling. Different agonists, e.g. prostanoids or nitric oxide (NO) increase the intracellular concentrations of the 
second messengers cyclic adenosine monophosphate (cAMP) and guanosine monophosphate (cGMP). Phosphodiesterase 
(PDE) inhibitors stabilize the second messengers and amplify the efficacy of the agonists. 8MM-IBMX selectively blocks PDE1 
which can hydrolyze both cyclic nucleotides. Motapizone inhibits PDE3, which hydrolyzes cAMP and is inhibitable by cGMP. 
Sildenafil blocks PDE5 and PDE1 and can therefore influence the cAMP and cGMP pathway. IP-R, prostacyclin receptor; AC, 
adenylate cyclase; sGC, soluble guanylate cyclase; smc, smooth muscle cell; PDE, phosphodiesterase.
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bination of sildenafil and motapizone. Combination of
low dose systemic PDE inhibitors might thus be
considered for enhancement and in particular prolonga-
tion of the lung vasorelaxant response to inhaled iloprost.
Abbreviations
PPA, mean pulmonary artery pressure; PSA, mean aortic
pressure; CO, cardiac output; U46619, stable
thromboxane-A2  analogue; PDE, phosphodiesterase;
Mota, motapizone; Sil, sildenafil; Ilo, iloprost.
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